Trump's FDA Pick Heidi Overton Faces Make-or-Break Senate Vote Next Week

Dr. Heidi Overton, President Donald Trump's pick to run the Food and Drug Administration, is staring down a Senate Health Committee vote on Nov. 18 — and the math is ugly. Republicans hold just a one-vote edge on the panel, meaning a single GOP defection dooms her if Democrats stay united against her. With Democrats taking the Senate in January, the GOP is racing the clock to push Trump's nominees through.

Committee chair Sen. Bill Cassidy, R-La., a physician, said Wednesday he's still undecided after meeting Overton earlier in the week. He has hammered her involvement in administration efforts to scale back childhood vaccination recommendations, once calling that role 'almost disqualifying.' In a Wednesday statement, he cited 'the lack of trust that exists due to broken promises and irresponsible decisions from other officials within the Administration.' Cassidy also acknowledged other Republican members of the committee haven't made up their minds.

Sens. Susan Collins of Maine and Lisa Murkowski of Alaska have flagged concerns too, while Sen. Josh Hawley of Missouri wants tougher restrictions on abortion drugs. That fight is the sharpest thorn: the administration has kept defending Biden-era rules that scrapped in-person dispensing requirements for mifepristone (Mifeprex), letting the pill be prescribed by telehealth and mailed to patients — even in states where abortion is restricted or illegal.

On Wednesday, Susan B. Anthony Pro-Life America urged senators to stall Overton's confirmation until the White House commits to reversing the mail-order policy. 'Confirmation is not a coronation,' said Erik Baptist, the group's senior vice president of legal strategy, who called it 'a tragedy that the Biden-era mail-order abortion drug regime remains in effect because the Trump administration has thus far chosen to defend and enforce it.' The organization estimates 15,000 abortions happen monthly in pro-life states because of pills obtained by mail.

SBA Pro-Life America also blasted the FDA's planned safety review of mifepristone, demanding broader Medicaid and private insurance data, independent expert input and more transparency. The agency has previously found the drug safe and effective when used as directed, and abortion-rights advocates say telehealth access matters for patients facing geographic and legal barriers. Critics counter that the FDA leaned on an unusual approval pathway, under-evaluated certain risks and eased safeguards without enough evidence.

Overton has previously criticized loosening mifepristone dispensing rules, but declined during her September confirmation hearing to prejudge the agency's ongoing review. Even a committee win next Wednesday only gets her to the full Senate — where the vaccine, abortion and health-agenda divides make the outcome anything but locked.